RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Financial and othersThey have the dosing and Tesamorelin is safe, how many drugs have been pulled from market during post approval phase or behind due to safety?
Today's market reaction imo if based on NASH news was not warranted as there were zero credit built in the valuation for the program. The fact that EMA is onboard and that was a big issue for many is positive news , the fact that harmonized protocol is competed is positive news, the fact that they are actively looking for partnership to move on with program both in the US and Europe is positive news, the fact that only 6 phase 3 trials are chasing a multi billion dollar market and THTX's program can join that group of very few companies in the space is positive news. The cost sharing and de-risking the program is correct strategic decision, I would say that even if they didn't need to add the futility analysis to the protocol
the partnership route would be the best option this is a small biotech with limited resources how many times have we seen small biotechs go than the partnership route due to financial risks. It's a common practice and in my opinion it is not indicative of strength or weakness of the program it's just not feasible for THTX to take on both oncology and NASH unless the oncology results are great later on during the process. Between now and then thie partnership is a sensible approach.